Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerNPI Medicare & MedicaidCirculogene Theranostics
    Ask Trek AI about this page

    Circulogene Theranostics — Billing Profile & Reimbursement Data

    NPI 1730558602 · XX · healthcare

    Customize your policy alerts

    Sign up for Circulogene Theranostics — Billing Profile & Reimbursement Data policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Circulogene Theranostics is a healthcare provider located in Unspecified Location. This profile covers 5 Medicare and 0 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services. Note: "XX" is a placeholder CMS uses when a provider's practice-location state wasn't reported — not a traditional US state; claims coded under it are grouped and benchmarked here the same way a traditional state would be.

    Provider details (source: NPPES NPI Registry)

    FieldValue
    Entity TypeIndividual
    OrganizationCirculogene Theranostics
    Address
    City
    StateXX (Unspecified Location)
    ZIP
    TaxonomyN/A
    NPI Enumerated
    NPI DeactivatedMarch 12, 2024

    (source: CMS Medicare & Medicaid claims data)

    Key Findings

    Circulogene Theranostics reports $2.3M in lifetime Medicare revenue and has no Medicaid billing on file, making its public payer footprint effectively single‑payer (Medicare) in the available data. The absence of any Medicaid claims suggests Medicaid is not a current revenue source and limits in‑state payer comparisons.

    Revenue is highly concentrated in a small set of complex molecular tests: the precomputed top three Medicare codes account for 98.5% of this provider's total Medicare revenue. That concentration indicates the business is narrowly focused on a few high‑value services rather than a broad portfolio of routine billing codes.

    The dominant code is 81455, which generated $1.7M in revenue (75.9% of this provider's Medicare revenue) across 599 claims at $2857 avg paid/claim. 81194 produced $304.3K (13.5%) with 599 claims at $508 avg paid/claim, and 81301 produced $204.9K (9.1%) with 599 claims at $342 avg paid/claim; together these three drive nearly all Medicare revenue.

    Medicare: Total Revenue Breakdown by CPT/HCPCS Code

    Medicare revenue breakdown by CPT/HCPCS procedure code.

    View: Bar Chart1 / 2

    Medicare Revenue by CPT/HCPCS Code

    Medicare: Complete Services Breakdown

    The CPT/HCPCS codes generating the most Medicare revenue for this provider.

    5 rows

    CPT/HCPCS CodeDescriptionClaimsAvg PaidRevenue
    81455The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to…600$2,860$1.7M
    81194The lab analyst performs the technical lab test using a specimen such as formalin–fixed paraffin embedded tissue (FFPE) to analyze NTRK (neurotrophic receptor tyrosine kinase) translocations for the…600$510$304.3K
    81301The lab analyst performs the technical lab test to detect the presence of microsatellite instability, also known as MSI, in tumor cells from tissue specimens such as colon cancer.600$340$204.9K
    81435The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen for genetic sequences of at least five genes, which relate to hereditary colon cancer–related disorders.…30$570$17.8K
    81436– WARNING – Code Deleted 2024‑12‑3130$570$16.6K

    Medicare: Competitive Analysis & Benchmarks

    How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes. Note: this provider's state, "XX," is a placeholder CMS uses when a provider's practice-location state wasn't reported — not a traditional US state; the State panel below benchmarks against other providers coded under the same designation.

    View: State1 / 2

    Claims Volume vs. Unspecified Location Distribution
    Circulogene Theranostics — 0 of 0 codes billed far more than typical (above p95)
    p5–p95 (all providers)p25–p75MedianThis providerOutlier
    Rank Distribution — Unspecified Location

    Full comparison — all codes billed, vs. state median

    5 rows

    CPT/HCPCS CodeRankProvider CountMedian ClaimsAvg PaidAverage Revenue
    8119410N/A$N/A$N/A
    8130110N/A$N/A$N/A
    8143510N/A$N/A$N/A
    8143610N/A$N/A$N/A
    8145510N/A$N/A$N/A

    Frequently Asked Questions

    References

    1. 1.Medicare Physician & Other Practitioner by Provider and Service. CMS.gov.Provider-level Medicare Part B utilization and payment data.
    2. 2.NPPES NPI Registry. CMS.gov.National Provider Identifier registry used for provider enumeration and taxonomy metadata.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    Lifetime revenue by payer source
    Payer SourceTotal Paid
    Medicare$2.3M
    Medicaid$0

    Code descriptions and the top codes themselves indicate Circulogene operates as a clinical molecular diagnostics lab focused on oncology genomic profiling: 81455 is a broad genomic panel for cancer, 81194 targets NTRK translocations, and 81301 tests microsatellite instability (MSI). The uniform claim counts (599 on each of the top three codes) and high average paid/claim values are consistent with centralized lab processing of high‑complexity oncology tests rather than point‑of‑care or episodic outpatient services.

    Competitive standing is mixed across codes: 81455 ranks #8 of 36 providers nationally (80th percentile) which is a respectable but not dominant position for large panel testing, while 81194 ranks #2 of 7 providers nationally (83th percentile) and 81301 ranks #2 of 20 providers nationally (95th percentile), indicating relatively stronger standing in NTRK and MSI testing within their peer sets. The supplied statistical labels classify these volumes as typical, unremarkable for each code, so the provider is not an extreme outlier in per‑code volume despite concentrating revenue.

    Smaller codes contribute only marginal revenue: 81435 produced $17.8K (0.8% of Medicare revenue) over 31 claims at $573 avg paid/claim and ranks #4 of 8 (57th percentile), and 81436 produced $16.6K (0.7%) over 29 claims and ranks #3 of 4 (33th percentile). These ancillary hereditary/targeted panels represent a tiny share of overall Medicare billing and are not material to the provider's revenue mix.

    Because the provider's NPI enumeration status, city, state, and taxonomy are listed as unknown, tenure and market context cannot be assessed from the available records. The lack of identifiable location and taxonomy limits geographic peer comparisons and makes it difficult to place the provider within a local competitive or referral network.

    Although the provider’s revenue is concentrated in high‑complexity oncology molecular tests, the provided statistical descriptors label activity on the top codes as typical, unremarkable volume; this suggests Circulogene’s operational footprint is specialized but not atypical in national peer comparisons. Analysts should therefore view the provider as a focused molecular diagnostics lab with meaningful Medicare revenue exposure concentrated in a few oncology assays, rather than as an anomalous high‑volume outlier.